Claude

The Full Story

The Cigna Group's narrative over the past five years is the story of a company that executed one of the most consequential strategic pivots in managed care: transforming from a diversified global health insurer into a pharmacy-services-first enterprise powered by Evernorth. Management has methodically divested non-core assets – Group Disability and Life to New York Life (2020), international supplemental businesses to Chubb (2022), and Medicare Advantage to HCSC (2025) – while doubling down on pharmacy volume growth. Adjusted income from operations has grown steadily from $6.8B to $8.0B, but the narrative tension lies in whether Evernorth's accelerating revenue (now $235B, up from $132B in FY2021) can sustain margin compression while the Cigna Healthcare segment faces rising medical cost ratios. Management credibility is moderate: they have consistently delivered on adjusted EPS targets but the VillageMD investment produced a $2.7B write-down that was never adequately foreshadowed.

The Narrative Arc

The arc moves in one direction: from a diversified global health conglomerate toward a focused pharmacy-and-services machine. Each divestiture removed earnings volatility and regulatory complexity, but also shed premium revenue and margin. The company's revenue has grown from $174B (FY2021) to $275B (FY2025), yet nearly all that growth comes from pharmacy pass-through revenue in Evernorth, which carries structurally thin margins.

The chart reveals the story visually: Evernorth's share of total revenue grew from 62% in FY2019 to 86% in FY2025. This is not a balanced two-platform company anymore – it is an Evernorth company with an attached health benefits business.

What Management Emphasized – and Then Stopped Emphasizing

What appeared and grew:

• Contract affordability has been the consistent drumbeat since FY2022, reflecting Evernorth's core value proposition of extracting purchasing savings for clients.
• Rebate transparency surged from zero to dominant in FY2025, driven by the announced rebate-free model – a preemptive response to FTC scrutiny and political pressure on PBM pricing.
• "Commitments to Better" emerged in FY2025 as a new framework: easier access, better support, better value, accountability, and transparency. This reads as a defensive rebranding in response to public and regulatory hostility toward PBMs and managed care companies.
• Strategic optimization reappeared forcefully in FY2025 ($749M in charges, targeting $500M+ in annualized savings).

What quietly faded:

• "Affordable, predictable and simple" – the tagline that defined Cigna's mission for years – vanished entirely by FY2025, replaced by "improve the health and vitality of those we serve."
• "Two growth platforms" language weakened as Cigna Healthcare shrank relative to Evernorth.
• Medicare Advantage growth went from a highlighted growth driver in FY2021 (87% of MA customers in 4-star plans) to a divested business by FY2025.
• Value-based care emphasis faded as the company shifted away from risk-bearing insurance.

Risk Evolution

The most striking risk evolution is FTC/antitrust scrutiny, which went from non-existent in FY2021 to critical by FY2024-2025. The FTC filed an administrative complaint against Express Scripts and two other PBMs in September 2024 over insulin rebate practices. While Cigna reached a settlement in February 2026 without monetary penalty, the settlement requires changes to business practices – and the ongoing political spotlight on PBMs represents the single largest existential risk to the Evernorth model.

Drug pricing legislation intensified steadily as the Inflation Reduction Act (2022) introduced Medicare drug price negotiation, insulin cost caps, and Part D benefit redesign. The FY2025 risk factors explicitly mention the rebate-free model as both a strategic response and a source of risk.

Client concentration rose as Evernorth's dependence on mega-clients grew. The Centene contract (effective January 2024, ~20M lives) was transformative for volume but created concentration risk. The FY2025 filing notes that the three largest clients have been renewed through the end of the decade, partially de-risking this factor.

How They Handled Bad News

The VillageMD Debacle (FY2022-2024)

In FY2022, Cigna committed to invest up to $2.7B in VillageMD preferred equity, describing it as "committed to offering high-quality, accessible primary care options." In January 2023, $2.5B was deployed. By Q3 2024, the entire investment was written down, resulting in a $2.7B impairment of equity securities and a separate $182M impairment of accrued dividend receivable.

Management's handling was opaque. The initial investment was framed as a strategic bet on value-based primary care delivery. When VillageMD's parent (Walgreens Boots Alliance) struggled and the investment deteriorated, management treated it as a below-the-line item excluded from adjusted earnings. The write-down compressed GAAP EPS to $12.12 in FY2024 while adjusted EPS showed a healthy $27.33. The gap between GAAP and adjusted earnings has been persistently wide – a recurring pattern at Cigna.

The Medicare Advantage Exit (FY2023-2025)

Cigna's Star Ratings deteriorated from 89% of MA customers in 4-star plans (FY2022 bonus payments) to an estimated 67% for FY2024-2025 bonus payments. Rather than invest to fix the ratings, management chose to sell the entire Medicare business to HCSC. The initial price of $3.3B grew to $4.9B at closing as statutory surplus increased.

This was handled more transparently than VillageMD. Management framed it as portfolio optimization, which was consistent with the broader simplification narrative. However, it also meant walking away from a market (Medicare Advantage) that peers like UnitedHealth and Humana have deemed central to their long-term strategy. The risk factor filings show the deteriorating Star Ratings made the economics untenable, but management never acknowledged the operational failures that caused the ratings decline.

Rising Medical Cost Ratio (FY2023-2025)

The medical care ratio has risen 560 basis points over three years. Management attributes this primarily to the IFP (Individual and Family Plans) business, but the trend suggests broader medical cost pressure. This was handled with limited proactive disclosure – the increases were acknowledged quarter by quarter without a comprehensive reset of expectations.

Guidance Track Record

Management has beaten adjusted EPS guidance every year from FY2021 through FY2025, though the beats have narrowed. The FY2025 beat ($29.84 vs ~$29.50) was the slimmest, suggesting the guide-and-beat cycle is compressing as the business matures. Importantly, management has shifted to a higher-growth EPS trajectory primarily through aggressive share buybacks: shares outstanding fell from ~340M (FY2021) to ~264M (FY2025), a 22% reduction. Without buybacks, EPS growth would have been materially lower.

Management earns a 7 out of 10 on credibility. The positive: consistent delivery on adjusted earnings, decisive portfolio management, and transparent communication on the divestiture strategy. The negatives: the VillageMD investment was a significant capital allocation failure with poor disclosure; the persistent $3B+ gap between GAAP and adjusted earnings requires investors to trust management's definition of "core" performance; and the MCR deterioration was inadequately flagged before it became a multi-year trend.

What the Story Is Now

The current story is this: Cigna Group is becoming a pharmacy services infrastructure company that happens to have a commercial health insurance business attached to it. Evernorth now generates 86% of revenue and 73% of pre-tax adjusted income. The announced rebate-free model is either a visionary preemptive move or a forced response to regulatory and political pressure – but either way, it signals that the traditional PBM spread-pricing model is ending.

What has been de-risked:

• The divestiture program is substantially complete. Medicare Advantage, international supplemental, and Group Disability and Life are all gone.
• The three largest Evernorth clients have been renewed through the end of the decade.
• The FTC settlement (February 2026) resolved the most acute regulatory threat without monetary penalty.
• Share buybacks have provided consistent EPS lift, with $10.3B in remaining authorization.

What still looks stretched:

• Evernorth's pre-tax margin has compressed from 4.2% (FY2023) to 3.1% (FY2025). The transition to a rebate-free model introduces near-term earnings uncertainty.
• The Cigna Healthcare medical care ratio at 84.4% is the highest in recent history, driven by IFP losses. Whether this stabilizes depends on pricing discipline.
• Debt-to-capitalization at 43% is elevated. The $4.5B bond issuance in September 2025 added leverage for the Shields Health Solutions investment – another capital allocation bet in the VillageMD mold.
• GAAP net income volatility remains high ($3.4B in FY2024, $6.0B in FY2025, vs steady $7-8B adjusted). Investors must decide whether to trust the adjusted metric.

What the reader should believe versus discount:

• Believe: The EPS growth algorithm (mid-to-high single digit adjusted EPS growth + buybacks) will likely continue for the next 2-3 years given renewed client contracts and efficiency savings.
• Discount: The claim that the rebate-free model will be margin-neutral. Management has acknowledged near-term earnings impact for Evernorth. The transition will test whether volume-based economics can replace spread-based economics.
• Watch closely: The MCR trajectory. If the IFP business continues to deteriorate, Cigna Healthcare's profit contribution could shrink further, making the company even more dependent on a single segment.

The area chart tells the final story: Evernorth's share of earnings has grown from 52% in FY2019 to 63% in FY2025, while Cigna Healthcare's contribution has flatlined. The narrative has shifted from "two complementary growth platforms" to "Evernorth with a health benefits complement." Whether investors are paying a PBM multiple or a managed care multiple for this company is the valuation question that everything else flows from.